Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

MeSH Review:

Peripheral Blood Stem Cell Transplantation

Schey, S. et al., Koizumi, K. et al., Advani, R. et al., Voermans, C. et al., Fukumoto, Y. et al., et al.

Horwitz, Uzel, Linton, Miller, Brown, Malech, Holland, Hiemenz, Cagnoni, Simpson, Devine, Chao, Keirns, Lau, Facklam, Buell, Scheulen, Hilger, Oberhoff, Casper, Freund, Josten, Bornhäuser, Ehninger, Berdel, Baumgart, Harstrick, Bojko, Wolf, Schindler, Seeber, Salar, Martino, Perea, Ribera, López-Guillermo, Guardia, Escoda, Altés, Sierra, Montserrat, Dispenzieri, Lacy, Kyle, Therneau, Larson, Rajkumar, Fonseca, Greipp, Witzig, Lust, Gertz, Nakao, Zeng, Yamazaki, Wang, Takami, Sugimori, Miura, Shiobara, Matsuda, Shinagawa, Harada, Tosi, Ronconi, Zamagni, Cellini, Grafone, Cangini, Pileri, Baccarani, Tura, Cavo, Karussis, Slavin, Dempke, Von Poblozki, Grothey, Schmoll,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Peripheral Blood Stem Cell Transplantation

DESIGN: Placebo or GM-CSF was administered after bone marrow or peripheral blood stem cell transplantation or both in a randomized, double-blind phase III trial by daily intravenous infusion (10 micrograms/kg body weight) until absolute neutrophil counts reached greater than or equal to 1000/mm3 on 3 consecutive days [1].
Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients [2].
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease [3].
Persistent Mycobacterium avium infection following nonmyeloablative allogeneic peripheral blood stem cell transplantation for interferon-gamma receptor-1 deficiency [4].
Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way [5].

Psychiatry related information on Peripheral Blood Stem Cell Transplantation

We have treated a series of 10 patients presenting with de novo (six) or relapsed (four) chronic lymphocytic leukaemia (CLL) with fludarabine as cytoreduction treatment and consolidation of the response with CD34 selected peripheral blood stem cell transplantation using cyclophosphamide and total body irradiation (TBI) as conditioning therapy [6].

High impact information on Peripheral Blood Stem Cell Transplantation

No useful predictor of risk of acute heart failure in peripheral-blood stem-cell transplantation (PBSCT) regimens, Including high-dose cyclophosphamide, has previously been available [7].
To investigate whether the migratory ability of peripheral blood-derived CD34+ cells of patients undergoing autologous peripheral blood stem cell transplantation is related to the homing efficiency of these cells, the migration in vitro of these cells was determined and correlated with in vivo hematopoietic recovery [8].
Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children [9]?
We have also shown that human MIP-1 alpha causes the rapid mobilization of hematopoietic cells, suggesting an additional clinical use in peripheral blood stem cell transplantation [10].
PATIENTS AND METHODS: The Mayo Clinic amyloid database was queried for all patients with AL seen at the Mayo Clinic from 1983 through 1997 who would have been eligible for peripheral-blood stem-cell transplantation [11].

Chemical compound and disease context of Peripheral Blood Stem Cell Transplantation

Induction of autologous graft-versus-host disease with cyclosporin A after peripheral blood stem cell transplantation: analysis of factors affecting induction [12].
CONCLUSIONS: This pilot study suggests that autologous graft-versus-host disease can be induced in recipients of autologous peripheral blood stem cell transplantation by cyclosporine or tacrolimus [13].
A Phase I dose escalation and pharmacokinetic study of the alkylating cytotoxic agent treosulfan was conducted to evaluate the maximum tolerated dose and the dose-limiting toxicities in patients with advanced malignancies rescued by autologous peripheral blood stem cell transplantation [14].
METHODS: Between June 1994 and June 2000, 15 patients with AL amyloidosis-associated ESRD were treated with intravenous melphalan (70 to 200 mg/m2) and autologous peripheral blood stem cell transplantation [15].
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) [16].

Biological context of Peripheral Blood Stem Cell Transplantation

We have performed a prospective study to evaluate early chimerism and its kinetics after allogeneic peripheral blood stem cell transplantation among 68 patients who received a reduced-intensity conditioning (RIC) regimen with fludarabine plus melphalan (n=40) or busulphan (n=28) [17].
Early establishment of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation in comparison with allogeneic bone marrow transplantation [18].
Acute immunosuppression with lymphocytic agents given at maximally tolerated doses, followed by hematopoietic stem cell rescue achieved by autologous bone marrow or peripheral blood stem cell transplantation (BMT), has proved effective in various experimental models of autoimmunity [19].
Transient improvement of left ventricular function after peripheral blood stem cell transplantation in a patient with myelodysplastic syndrome and dilated cardiomyopathy [20].

Anatomical context of Peripheral Blood Stem Cell Transplantation

T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation [21].
For the better understanding of engraftment properties after autologous peripheral blood stem cell transplantation (PBSCT), hematopoietic recovery, immune reconstitution and functional capacity of cytokine production in different lymphocyte populations were examined [22].
We describe a patient with acute myelogenous leukaemia who developed angina pectoris during pretransplant conditioning for autologous peripheral blood stem cell transplantation (PBSCT); the conditioning regimen consisted of cytotoxic drugs in combination with granulocyte colony-stimulating factor (G-CSF) [23].
We conclude that peripheral blood stem cell transplantation results in rapid recovery of neutrophils but variable recovery of platelets after high-dose busulfan and cyclophosphamide, when stem cells are harvested following priming with cyclophosphamide/etoposide and G-CSF [24].
Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion [25].

Associations of Peripheral Blood Stem Cell Transplantation with chemical compounds

In this dose escalation study, 74 adult cancer patients undergoing bone marrow or peripheral blood stem cell transplantation received fluconazole (400 mg/day) and either normal saline (control) (12 subjects) or micafungin (12.5 to 200 mg/day) (62 subjects) for up to 4 weeks [26].
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia [27].
Thirty patients with qualifying responses to VIP-E proceeded to high-dose chemotherapy (HDC) with autologous peripheral blood stem-cell transplantation (PBSCT) after etoposide (1,500 mg/m2), ifosfamide (12,000 mg/m2), carboplatin (750 mg/m2) and epirubicin (150 mg/m2) (VIC-E) conditioning [28].
IFOVM consisted of ifosfamide (10 g/m2 as a 72-hour continuous infusion), etoposide (900 mg/m2) and methylprednisolone; responding patients underwent two cycles of DHAP and subsequently an autologous peripheral blood stem cell transplantation (APBSCT) with BEAM as the conditioning regimen [29].
The present study was aimed at evaluating thalidomide as single agent therapy for patients who had previously received autologous peripheral blood stem cell transplantation [30].

Gene context of Peripheral Blood Stem Cell Transplantation

Prolonged molecular remission after PML/RAR alpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft [31]?
Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation [32].
TNFalpha, interleukin-10 and interleukin-18 expression in cells of the bronchoalveolar lavage in patients with pulmonary complications following bone marrow or peripheral stem cell transplantation: a preliminary study [33].
Recently, EPO has been shown to significantly accelerate hematopoietic reconstitution after peripheral blood stem cell transplantation (PBSCT) resulting in reduced infection rates [34].
This study suggests that if the expansion of CD34+/CD41+ is performed in vitro, the 6 days' culture of peripheral blood CD34+/CD41- cells with a combination of IL-3 and SCF with TPO provides the most rapid and stable products of CD34+/CD41+ cells for the rapid recovery of platelets in patients with peripheral blood stem cell transplantation [35].

Analytical, diagnostic and therapeutic context of Peripheral Blood Stem Cell Transplantation

Peripheral blood counts and factors influencing haematological recovery in 98 patients with a relapse-free survival of > or =1 year treated with high-dose chemotherapy (HDC) and peripheral stem-cell transplantation (PSCT) for haematological malignancies were analysed [36].
OBJECTIVE: The aim of this study was to evaluate which CD34(+) cell subset contained in leukapheresis products could be regarded as the most predictive of long-term hematopoietic recovery after autologous peripheral blood stem cell transplantation (auto-PBSCT) [37].
The impact of hemodialysis on the clearance of busulfan was determined in a patient with chronic renal failure undergoing autologous peripheral stem cell transplantation for non-Hodgkin's lymphoma [38].
We performed a retrospective study on recovery and survival of patients with T-cell NHL after autologous peripheral blood stem cell transplantation (APBSCT) [39].
Immunotherapy with interleukin-2 (IL-2) early after peripheral blood stem cell transplantation (PBSCT) is being considered as a potential way to eradicate minimal residual disease [40].

References

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Advani, R., Chao, N.J., Horning, S.J., Blume, K.G., Ahn, D.K., Lamborn, K.R., Fleming, N.C., Bonnem, E.M., Greenberg, P.L. Ann. Intern. Med. (1992) [Pubmed]
Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Gyger, M., Sahovic, E., Aslam, M. Blood (1998) [Pubmed]
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Kessinger, A., Bierman, P.J., Vose, J.M., Armitage, J.O. Blood (1991) [Pubmed]
Persistent Mycobacterium avium infection following nonmyeloablative allogeneic peripheral blood stem cell transplantation for interferon-gamma receptor-1 deficiency. Horwitz, M.E., Uzel, G., Linton, G.F., Miller, J.A., Brown, M.R., Malech, H.L., Holland, S.M. Blood (2003) [Pubmed]
Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way. Mehta, J., Singhal, S. J. Clin. Oncol. (2002) [Pubmed]
Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study. Schey, S., Ahsan, G., Jones, R. Bone Marrow Transplant. (1999) [Pubmed]
QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Nakamae, H., Tsumura, K., Hino, M., Hayashi, T., Tatsumi, N. Lancet (2000) [Pubmed]
In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. Voermans, C., Kooi, M.L., Rodenhuis, S., van der Lelie, H., van der Schoot, C.E., Gerritsen, W.R. Blood (2001) [Pubmed]
Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children? Ojeda, E., Garcia-Bustos, J., Agaudo, M.J., Quevedo, E., Arrieta, R., Jimenez, V., Canales, M., Hernandez-Navarro, F. Blood (1999) [Pubmed]
BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. Hunter, M.G., Bawden, L., Brotherton, D., Craig, S., Cribbes, S., Czaplewski, L.G., Dexter, T.M., Drummond, A.H., Gearing, A.H., Heyworth, C.M., Lord, B.I., McCourt, M., Varley, P.G., Wood, L.M., Edwards, R.M., Lewis, P.J. Blood (1995) [Pubmed]
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. Dispenzieri, A., Lacy, M.Q., Kyle, R.A., Therneau, T.M., Larson, D.R., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A., Gertz, M.A. J. Clin. Oncol. (2001) [Pubmed]
Induction of autologous graft-versus-host disease with cyclosporin A after peripheral blood stem cell transplantation: analysis of factors affecting induction. Miura, Y., Ueda, M., Zeng, W., Wang, H., Takami, A., Yamazaki, H., Kawamura, Y., Shiobara, S., Nakao, S. J. Allergy Clin. Immunol. (2000) [Pubmed]
Induction of autologous graft-versus-host disease after autologous peripheral blood stem cell transplantation. Nakamura, H., Nakao, T., Ujiie, H., Karasuno, T., Teshima, H., Komatsu, K., Ishiguro, S., Hiraoka, A., Masaoka, T. J. Allergy Clin. Immunol. (1999) [Pubmed]
Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Scheulen, M.E., Hilger, R.A., Oberhoff, C., Casper, J., Freund, M., Josten, K.M., Bornhäuser, M., Ehninger, G., Berdel, W.E., Baumgart, J., Harstrick, A., Bojko, P., Wolf, H.H., Schindler, A.E., Seeber, S. Clin. Cancer Res. (2000) [Pubmed]
High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Casserly, L.F., Fadia, A., Sanchorawala, V., Seldin, D.C., Wright, D.G., Skinner, M., Dember, L.M. Kidney Int. (2003) [Pubmed]
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Fischer, T., Reifenrath, C., Hess, G.R., Corsetti, M.T., Kreil, S., Beck, J., Meinhardt, P., Beltrami, G., Schuch, B., Gschaidmeier, H., Hehlmann, R., Hochhaus, A., Carella, A., Huber, C. Leukemia (2002) [Pubmed]
Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Valcárcel, D., Martino, R., Caballero, D., Mateos, M.V., Pérez-Simón, J.A., Canals, C., Fernández, F., Bargay, J., Muñiz-Díaz, E., Gonzalez, M., San Miguel, J.F., Sierra, J. Bone Marrow Transplant. (2003) [Pubmed]
Early establishment of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation in comparison with allogeneic bone marrow transplantation. Nakao, S., Zeng, W., Yamazaki, H., Wang, H., Takami, A., Sugimori, N., Miura, Y., Shiobara, S., Matsuda, T., Shinagawa, Y., Harada, M. Eur. J. Haematol. (1999) [Pubmed]
Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures. Karussis, D., Slavin, S. J. Neurol. Sci. (2004) [Pubmed]
Transient improvement of left ventricular function after peripheral blood stem cell transplantation in a patient with myelodysplastic syndrome and dilated cardiomyopathy. Ogawa, K., Yaoita, H., Okamoto, M., Ikeda, K., Shichishima, T., Ohto, H., Maehara, K., Maruyama, Y. Circ. J. (2004) [Pubmed]
T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Baron, F., Schaaf-Lafontaine, N., Humblet-Baron, S., Meuris, N., Castermans, E., Baudoux, E., Frère, P., Bours, V., Fillet, G., Beguin, Y. Transplantation (2003) [Pubmed]
Immune reconstitution and production of intracellular cytokines in T lymphocyte populations following autologous peripheral blood stem cell transplantation. Schlenke, P., Sheikhzadeh, S., Weber, K., Wagner, T., Kirchner, H. Bone Marrow Transplant. (2001) [Pubmed]
Angina pectoris occurring during granulocyte colony-stimulating factor-combined preparatory regimen for autologous peripheral blood stem cell transplantation in a patient with acute myelogenous leukaemia. Fukumoto, Y., Miyamoto, T., Okamura, T., Gondo, H., Iwasaki, H., Horiuchi, T., Yoshizawa, S., Inaba, S., Harada, M., Niho, Y. Br. J. Haematol. (1997) [Pubmed]
Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. Ballester, O.F., Agaliotis, D.P., Hiemenz, J.W., Janssen, W.E., Fields, K.K., Zorksy, P.E., Goldstein, S.C., Perkins, J.B., Elfenbein, G.J. Bone Marrow Transplant. (1996) [Pubmed]
Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. Baron, F., Frère, P., Fillet, G., Beguin, Y. Br. J. Haematol. (2003) [Pubmed]
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Hiemenz, J., Cagnoni, P., Simpson, D., Devine, S., Chao, N., Keirns, J., Lau, W., Facklam, D., Buell, D. Antimicrob. Agents Chemother. (2005) [Pubmed]
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. Schlenk, R.F., Hartmann, F., Hensel, M., Jung, W., Weber-Nordt, R., Gabler, A., Haas, R., Ho, A.D., Trümper, L., Döhner, H. Leukemia (2002) [Pubmed]
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. Fetscher, S., Brugger, W., Engelhardt, R., Kanz, L., Hasse, J., Frommhold, H., Lange, W., Mertelsmann, R. Ann. Oncol. (1999) [Pubmed]
High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma. Salar, A., Martino, R., Perea, G., Ribera, J.M., López-Guillermo, A., Guardia, R., Escoda, L., Altés, A., Sierra, J., Montserrat, E. Haematologica (2002) [Pubmed]
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Tosi, P., Ronconi, S., Zamagni, E., Cellini, C., Grafone, T., Cangini, D., Pileri, S.A., Baccarani, M., Tura, S., Cavo, M. Haematologica (2001) [Pubmed]
Prolonged molecular remission after PML/RAR alpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft? Sanz, M.A., de la Rubia, J., Bonanad, S., Barragán, E., Sempere, A., Martín, G., Martínez, J.A., Jiménez, C., Cervera, J., Bolufer, P., Sanz, G.F. Leukemia (1998) [Pubmed]
Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Eder, M., Battmer, K., Kafert, S., Stucki, A., Ganser, A., Hertenstein, B. Leukemia (1999) [Pubmed]
TNFalpha, interleukin-10 and interleukin-18 expression in cells of the bronchoalveolar lavage in patients with pulmonary complications following bone marrow or peripheral stem cell transplantation: a preliminary study. Hauber, H.P., Mikkilä, A., Erich, J.M., Kröger, N., Meyer, A., Schoder, V., Zander, A.R., Pforte, A. Bone Marrow Transplant. (2002) [Pubmed]
Human hematopoietic growth factors: old lessons and new perspectives. Dempke, W., Von Poblozki, A., Grothey, A., Schmoll, H.J. Anticancer Res. (2000) [Pubmed]
In vitro expansion of CD34+/CD41+ cells from human peripheral blood CD34+/CD41- cells: role of cytokines for in vitro proliferation and differentiation of megakaryocytic progenitors. Koizumi, K., Sawada, K., Yamaguchi, M., Notoya, A., Tarumi, T., Takano, H., Fukada, Y., Nishio, M., Katagiri, E., Yasukouchi, T., Sato, N., Sekiguchi, S., Koike, T. Exp. Hematol. (1998) [Pubmed]
Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. Nieboer, P., de Vries, E.G., Vellenga, E., van der Graaf, W.T., Mulder, N.H., Sluiter, W.J., de Wolf, J.T. Eur. J. Cancer (2004) [Pubmed]
CD34(+) cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation. Lanza, F., Campioni, D., Moretti, S., Dominici, M., Punturieri, M., Focarile, E., Pauli, S., Dabusti, M., Tieghi, A., Bacilieri, M., Scapoli, C., De Angeli, C., Galluccio, L., Castoldi, G. Exp. Hematol. (2001) [Pubmed]
Busulfan clearance in renal failure and hemodialysis. Ullery, L.L., Gibbs, J.P., Ames, G.W., Senecal, F.M., Slattery, J.T. Bone Marrow Transplant. (2000) [Pubmed]
Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Kim, H., Sohn, H.J., Kim, S.E., Kang, H.J., Park, S., Kim, S., Kim, W.K., Lee, J.S., Suh, C. Bone Marrow Transplant. (2004) [Pubmed]
Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Neubauer, M.A., Benyunes, M.C., Thompson, J.A., Bensinger, W.I., Lindgren, C.G., Buckner, C.D., Fefer, A. Bone Marrow Transplant. (1994) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.